Why we just sold Zip and bought Pro Medicus (ASX:PME) shares: fundie

Why sell-off Zip for Pro Medicus?

| More on:
A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Pro Medicus share price has slipped more than 4% at the time of writing while Zip is down almost 3%
  • An investment head at Abrdn has revealed the reason for a pivot from Zip to Pro Medicus 
  • Pro Medicus reported a nearly 53% surge in its net profit after tax in its half-yearly results 

A high-level funds manager has divulged her fund's strategy of offloading Zip Co Ltd (ASX: Z1P) shares and buying Pro Medicus Ltd (ASX: PME) instead.

The Pro Medicus share price is down 4.48% at the time of writing at $44.10, after falling as low as $43.59 earlier today. Meanwhile, Zip shares are around 2.62% lower.

By comparison, the S&P/ASX 200 Index (ASX: XJO) is down around 1% so far today.

Let's take a look at what the Australian head of one global investment firm had to say.

Why Pro Medicus instead of Zip?

Amid interest rate speculation, the Russian invasion of Ukraine, and the east coast floods, one investment head has outlined reasons for a shift towards a growth share like Pro Medicus over buy now, pay later (BNPL) share Zip.

Speaking to LiveWire, Abrdn Australian equities head Michelle Lopez explained her fund's major portfolio shift with its move to a growth share like Pro Medicus.

So we pivoted out of a company, for example, Zip, that had a very long runway to turn profitable. And we recycled that capital into a higher quality growth name, such as a Pro Medicus, that again, got hit very hard. 

But, A, it's profitable, B, it's got incredibly strong margins. It's an industry leader. It's got cash on the balance sheet. And again, we felt the valuation had come off a long way. So it was just being a lot more discriminate in quality growth versus lower quality growth.

In its half-yearly results, Pro Medicus reported net profit surged by 52.7% and revenue increased by 40%. The company's shares gained 3.6% on 16 February, the day these figures were released.

Lopez also shared her insight into the latest reporting season, describing it as "turbulent". She added:

We've had rising inflation, we've got interest rates and expectations of hikes coming through, and we've got geopolitical tensions escalating. I felt it was a case of "shoot first and ask questions later" this reporting season.

Particularly for companies that had either very high valuations or operating leverage that was expected to come through that didn't, they're the ones that really got hit quite hard.

The Pro Medicus share price has sunk 26% in the past six months while the Zip share price has tanked 76% over the same time frame.

Share price recap

The Pro Medicus share price has held steady during the past 12 months, gaining a modest 0.75%, while Zip shares have shed around 83%.

For comparison, the benchmark ASX 200 index has returned about 5% over the past year.

Year to date, Pro Medicus shares have dived nearly 30%, while Zip shares have slumped around 62%.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Pro Medicus Ltd. and ZIPCOLTD FPO. The Motley Fool Australia owns and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »